Page last updated: 2024-08-16

pioglitazone and l-165041

pioglitazone has been researched along with l-165041 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM1
Blöcher, R; Hahn, S; Klingler, FM; la Buscató, E; Lamers, C; Proschak, E; Schubert-Zsilavecz, M; Steinhilber, D1
Angioni, C; Blöcher, R; Boß, M; Brüggerhoff, A; Brüne, B; Diehl, O; Geisslinger, G; Göbel, T; Grundmann, M; Hartmann, M; Heering, J; Kahnt, AS; Kaiser, A; Kostenis, E; Lamers, C; Merk, D; Proschak, E; Schader, T; Schubert-Zsilavecz, M; Steinhilber, D; Weizel, L; Wittmann, SK; Wurglics, M1
Ammazzalorso, A; Amoroso, R; Brunetti, L; Bruno, I; Cama, A; Capone, F; Cerchia, C; De Filippis, B; Fantacuzzi, M; Ferrante, C; Florio, R; Giampietro, L; Laghezza, A; Lavecchia, A; Loiodice, F; Maccallini, C; Recinella, L; Tortorella, P; Verginelli, F1
Futawaka, K; Kasahara, M; Li, JE; Liu, TH; Moriyama, K; Tagami, T; Yamamoto, H1

Reviews

1 review(s) available for pioglitazone and l-165041

ArticleYear
The PPARs: from orphan receptors to drug discovery.
    Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4

    Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2000

Other Studies

4 other study(ies) available for pioglitazone and l-165041

ArticleYear
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.
    Journal of medicinal chemistry, 2012, Dec-13, Volume: 55, Issue:23

    Topics: Chromatography, High Pressure Liquid; Drug Interactions; Epoxide Hydrolases; Magnetic Resonance Spectroscopy; Mass Spectrometry; Peroxisome Proliferator-Activated Receptors; Solubility

2012
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.
    Journal of medicinal chemistry, 2016, Jan-14, Volume: 59, Issue:1

    Topics: 3T3 Cells; Administration, Oral; Animals; Benzamides; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Hypertension; In Vitro Techniques; Metabolic Syndrome; Mice; Microsomes, Liver; PPAR gamma; Rats; Structure-Activity Relationship

2016
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
    ACS medicinal chemistry letters, 2019, Apr-11, Volume: 10, Issue:4

    Topics:

2019
Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARδ, PPARγ, and RXR.
    The American journal of Chinese medicine, 2015, Volume: 43, Issue:5

    Topics: Acrolein; Adipocytes; Cinnamomum zeylanicum; Drug Synergism; Energy Metabolism; Fatty Acids; Gene Expression; HEK293 Cells; Humans; Insulin Resistance; Muscle, Skeletal; Oxidation-Reduction; Phenoxyacetates; Pioglitazone; PPAR delta; PPAR gamma; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stimulation, Chemical; Thiazolidinediones; Transcription, Genetic; Up-Regulation

2015